Nail psoriasis: A review

American Journal of Clinical Dermatology

Volumn 13, Issue 6, 2012, Pages 375-388

  Tan, Eugene S T ^a   Chong, Wei Sheng ^a   Tey, Hong Liang ^a  

^a NATIONAL SKIN CENTRE   (Singapore)

Author keywords

Adalimumab; Alefacept; Ciclosporin; Corticosteroids; Dithranol; Etanercept; Fluorouracil; Hyperkeratosis; Infliximab; Laser therapy; Methotrexate; Nail disorders; Onycholysis; Photochemotherapy; Psoriasis; Psoriatic arthritis; Quality of life; Retinoids; Tazarotene; Tumour necrosis factors; Ustekinumab; Vitamin D analogues

Indexed keywords

ADALIMUMAB; ALEFACEPT; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCIPOTRIOL; CLOBETASOL PROPIONATE; COLECALCIFEROL DERIVATIVE; CORTICOSTEROID; CYCLOSPORIN A; DITHRANOL; ETANERCEPT; FLUOROURACIL; INFLIXIMAB; METHOTREXATE; RETINOID; TAZAROTENE; UNCLASSIFIED DRUG; USTEKINUMAB; XAMIOL;

CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HISTOPATHOLOGY; HUMAN; HYPERKERATOSIS; NAIL DISEASE; NAIL PSORIASIS; ONYCHOLYSIS; PATHOPHYSIOLOGY; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW;

ARTHRITIS, PSORIATIC; DERMATOLOGIC AGENTS; DISEASE PROGRESSION; HUMANS; IMMUNOLOGIC FACTORS; LASER THERAPY; NAIL DISEASES; PHOTOCHEMOTHERAPY; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 84867419502     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11597000-000000000-00000     Document Type: Review

References (99)

1. Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: A population-based study. Arch Dermatol 2005; 141: 1537-41
2. Plunkett A, Marks R. A review of the epidemiology of psoriasis vulgaris in the community. Australas J Dermatol 1998; 39: 225-32
3. Icen M, Crowson CS, McEvoy MT, et al. Trends in incidence of adult-onset psoriasis over three decades: A population-based study. J Am Acad Dermatol 2009; 60: 394-401
4. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: Epidemiology, clinical features, course, and outcome. Ann RheumDis 2005; 64 Suppl. 2: 14-7
5. Gladman DD, Anhorn KB, Schachter RK, et al. HLA antigens in psoriatic arthritis. J Rheumatol 1986; 13: 586-92
6. Cohen MR, Reda DJ, Clegg DO. Baseline relationships between psoriasis and psoriatic arthritis: Analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies. J Rheumatol 1999; 26: 1752-6
7. Samman PD, Fenton DA. The nails in disease. 5th ed. London: Butterworth-Heinemann Ltd., 1994
8. Van Laborde S, Scher RK. Developments in the treatment of nail psoriasis, melanonychia striata, and onychomycosis: A review of the literature. Dermatol Clin 2000; 18: 37-46
9. Augustin M, Reich K, Blome C, et al. Nail psoriasis in Germany: Epidemiology and burden of disease. Br J Dermatol 2010; 163: 580-5
10. Kundakci N, Tu rsen U, Babiker MO, et al. The evaluation of the sociodemographic and clinical features of Turkish psoriasis patients. Int J Dermatol 2002; 41: 220-4
11. Chang CC, Gangaram HB, Hussein SH. Malaysian Psoriasis Registrypreliminary report of a pilot study using a newly revised registry form. Med J Malaysia 2008; 63 Suppl. C: 68-71
12. Myers WA, Gottlieb AB, Mease P. Psoriasis and psoriatic arthritis: Clinical features and disease mechanisms. Clin Dermatol 2006; 24: 438-47
13. Tham SN, Lim JJ, Tay SH, et al. Clinical observations on nail changes in psoriasis. Ann Acad Med Singapore 1988; 17: 482-5
14. Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007; 57: 1-27
15. Rich P, Scher RK. Nail Psoriasis Severity Index: A useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003; 49: 206-12
16. de Berker D. Management of nail psoriasis. Clin Exp Dermatol 2000; 25: 357-62
17. Edwards F, de Berker D. Nail psoriasis: Clinical presentation and best practice recommendations. Drugs 2009; 69: 2351-61
18. Kovich OI, Soldano AC. Clinical pathologic correlations for diagnosis and treatment of nail disorders. Dermatol Ther 2007; 20: 11-6
19. Natarajan V, Nath AK, Thappa DM, et al. Coexistence of onychomycosis in psoriatic nails: A descriptive study. Indian J Dermatol Venereol Leprol 2010; 76: 723
20. Saladi RN, Persaud AN, Rudikoff D, et al. Idiopathic splinter hemorrhages. J Am Acad Dermatol 2004; 50: 289-92
21. Frances C, Piette JC, Saada V, et al. Multiple subungual splinter hemorrhages in the antiphospholipid syndrome: A report of five cases and review of the literature. Lupus 1994; 3: 123-8
22. Jones SM, Armas JB, Cohen MG, et al. Psoriatic arthritis: Outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol 1994; 33: 834-9
23. Tan AL, Grainger AJ, Tanner SF, et al. A high-resolution magnetic resonance imaging study of distal interphalangeal joint arthropathy in psoriatic arthritis and osteoarthritis: Are they the same? Arthritis Rheum 2006; 54: 1328-33
24. Tan AL, Benjamin M, Toumi H, et al. The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis: A high-resolution MRI and histological study. Rheumatology (Oxford) 2007; 46: 253-6
25. McGonagle D. Enthesitis: An autoinflammatory lesion linking nail and joint involvement in psoriatic disease. J Eur Acad Dermatol Venereol 2009; 23 Suppl. 1: 9-13
26. Williamson L, Dalbeth N, Dockerty JL, et al. Extended report: nail disease in psoriatic arthritis: Clinically important, potentially treatable and often overlooked. Rheumatology (Oxford) 2004; 43: 790-4
27. Parrish CA, Sobera JO, Elewski BE. Modification of the Nail Psoriasis Severity Index. J Am Acad Dermatol 2005; 53: 745-6
28. Cassell SE, Bieber JD, Rich P, et al. The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol 2007; 34: 123-9
29. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): A simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-6
30. Ortonne JP, Baran R, Corvest M, et al. Development and validation of nail psoriasis quality of life scale (NPQ10). J Eur Acad Dermatol Venereol 2010; 24: 22-7
31. Tosti A, Piraccini BM, Cameli N, et al. Calcipotriol ointment in nail psoriasis: A controlled double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol 1998; 139: 655-9
32. Rigopoulos D, Ioannides D, Prastitis N, et al. Nail psoriasis: A combined treatment using calcipotriol cream and clobetasol propionate cream [letter]. Acta Derm Venereol 2002; 82: 140
33. Tzung TY, Chen CY, Yang CY, et al. Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. Acta Derm Venereol 2008; 88: 279-80
34. Wolf R, Tur E, Brenner S. Corticosteroid-induced 'disappearing digit'. J Am Acad Dermatol 1990; 23: 755-6
35. Deffer TA, Goette DK. Distal phalangeal atrophy secondary to topical steroid therapy. Arch Dermatol 1987; 123: 571-2
36. Scott LJ, Dunn CJ, Goa KL. Calcipotriol ointment: A review of its use in the management of psoriasis. Am J Clin Dermatol 2001; 2: 95-120
37. Fredriksson T. Topically applied fluorouracil in the treatment of psoriatic nails. Arch Dermatol 1974; 110: 735-6
38. de Jong EM, Menke HE, van Praag MC, et al. Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-enhancing vehicle: A double-blind study. Dermatology 1999; 199: 313-8
39. Kemeny L, Ruzicka T, Braun-Falco O. Dithranol: A review of the mechanism of action in the treatment of psoriasis vulgaris. Skin Pharmacol 1990; 3: 1-20
40. Yamamoto T, Katayama I, Nishioka K. Topical anthralin therapy for refractory nail psoriasis. J Dermatol 1998; 25: 231-3
41. Duvic M, Nagpal S, Asano AT, et al. Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol 1997; 37: S18-24
42. Scher RK, Stiller M, Zhu YI. Tazarotene 0.1%gel in the treatment of fingernail psoriasis: A double-blind, randomized, vehicle-controlled study. Cutis 2001; 68: 355-8
43. Bianchi L, Soda R, Diluvio L, et al. Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: An open, prospective study. Br J Dermatol 2003; 149: 207-9
44. Rigopoulos D, Gregoriou S, Katsambas A. Treatment of psoriatic nails with tazarotene cream 0.1%vs. clobetasol propionate 0.05%cream: A double-blind study. Acta Derm Venereol 2007; 87: 167-8
45. Weindl G, Roeder A, Scha fer-Korting M, et al. Receptor-selective retinoids for psoriasis: Focus on tazarotene. Am J Clin Dermatol 2006; 7: 85-97
46. Cannavo SP, Guarneri F, Vaccaro M, et al. Treatment of psoriatic nails with topical cyclosporin: A prospective, randomized placebo-controlled study. Dermatology 2003; 206: 153-6
47. Tosti A, Guerra L, Bardazzi F, et al. Topical ciclosporin in nail psoriasis [letter]. Dermatologica 1990; 180: 110
48. Hermann RC, Taylor RS, Ellis CN, et al. Topical ciclosporin for psoriasis: In vitro skin penetration and clinical study. Skin Pharmacol 1988; 1: 246-9
49. Prins AM, Vos K, Franssen EJ. Instability of topical ciclosporin emulsion for nail psoriasis. Dermatology 2007; 215: 362-3
50. Lin AN. Innovative use of topical calcineurin inhibitors. Dermatol Clin 2010; 28: 535-45
51. de Berker D. Management of psoriatic nail disease. Semin Cutan Med Surg 2009; 28: 39-43
52. Grover C, Bansal S, Nanda S, et al. Efficacy of triamcinolone acetonide in various acquired nail dystrophies. J Dermatol 2005; 32: 963-8
53. Saleem K, Azim W. Treatment of nail psoriasis with a modified regimen of steroid injections. J Coll Physicians Surg Pak 2008; 18: 78-81
54. de Berker DA, Lawrence CM. A simplified protocol of steroid injection for psoriatic nail dystrophy. Br J Dermatol 1998; 138: 90-5
55. Marx JL, Scher RK. Response of psoriatic nails to oral photochemotherapy. Arch Dermatol 1980; 116: 1023-4
56. Handfield-Jones SE, Boyle J, Harman RR. Local PUVA treatment for nail psoriasis. Br J Dermatol 1987; 116: 280-1
57. Stern DK, Creasey AA, Quijije J, et al. UV-A and UV-B penetration of normal human cadaveric fingernail plate. Arch Dermatol 2011; 147: 439-41
58. Hern S, Stanton AW, Mellor RH, et al. In vivo quantification of the structural abnormalities in psoriatic microvessels before and after pulsed dye laser treatment. Br J Dermatol 2005; 152: 505-11
59. Oram Y, Karincaog lu Y, Koyuncu E, et al. Pulsed dye laser in the treatment of nail psoriasis. Dermatol Surg 2010; 36: 377-81
60. Fernandez-Guarino M, Harto A, Sa nchez-Ronco M, et al. Pulsed dye laser vs. photodynamic therapy in the treatment of refractory nail psoriasis: A comparative pilot study. J Eur Acad Dermatol Venereol 2009; 23: 891-5
61. Finnerty EF. Successful treatment of psoriasis of the nails. Cutis 1979; 23: 43-4
62. Yu RC, King CM.Adouble-blind study of superficial radiotherapy in psoriatic nail dystrophy. Acta Derm Venereol 1992; 72: 134-6
63. Kwang TY, Nee TS, Seng KT. A therapeutic study of nail psoriasis using electron beams [letter]. Acta Derm Venereol 1995; 75: 90
64. Lindelof B. Psoriasis of the nails treated with grenz rays: A double-blind bilateral trial. Acta Derm Venereol 1989; 69: 80-2
65. Brazzelli V, Martinoli S, Prestinari F, et al. An impressive therapeutic result of nail psoriasis to acitretin. J Eur Acad Dermatol Venereol 2004; 18: 229-30
66. Lo pez V, Molina I, Marti N, et al. Severe nail psoriasis with a rapid response to acitretin. Clin Exp Dermatol 2009; 34: E332-3
67. Tosti A, Ricotti C, Romanelli P, et al. Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol 2009; 145: 269-71
68. Piraccini BM, Tosti A, Iorizzo M, et al. Pustular psoriasis of the nails: Treatment and long-term follow-up of 46 patients. Br J Dermatol 2001; 144: 1000-5
69. Sbidian E, Maza A, Montaudie H, et al. Efficacy and safety of oral retinoids in different psoriasis subtypes: A systematic literature review. J Eur Acad Dermatol Venereol 2011; 25: 28-33
70. Baran R. Etretinate and the nails (study of 130 cases) possible mechanisms of some side-effects. Clin Exp Dermatol 1986; 11: 148-52
71. Syuto T, Abe M, Ishibuchi H, et al. Successful treatment of psoriatic nails with low-dose cyclosporine administration. Eur J Dermatol 2007; 17: 248-9
72. Mahrle G, Schulze HJ, Farber L, et al. Low-dose short-term cyclosporine versus etretinate in psoriasis: Improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995; 32: 78-88
73. Feliciani C, Zampetti A, Forleo P, et al. Nail psoriasis: Combined therapy with systemic cyclosporin and topical calcipotriol. J Cutan Med Surg 2004; 8: 122-5
74. Gumusel M, Ozdemir M, Mevlitoglu I, et al. Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: A one-blind, randomized study. J Eur Acad Dermatol Venereol 2011 Sep; 25 (9): 1080-4
75. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: A Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009; 10: 816-24
76. Kothary N, Diak IL, Brinker A, et al. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol 2011; 65: 546-51
77. Hussain W, Coulson I, Owen C. Severe recalcitrant nail psoriasis responding dramatically to infliximab: Report of two patients. Clin Exp Dermatol 2008; 33: 520-2
78. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, doubleblind trial. Lancet 2005; 366: 1367-74
79. Reich K, Ortonne JP, Kerkmann U, et al. Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: A retrospective analysis of the EXPRESS Trial. Dermatology 2010; 221: 172-8
80. Rich P, Griffiths CE, Reich K, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008; 58: 224-31
81. Fabroni C, Gori A, Troiano M, et al. Infliximab efficacy in nail psoriasis. a retrospective study in 48 patients. J Eur Acad Dermatol Venereol 2011; 25: 549-53
82. Rigopoulos D, Gregoriou S, Stratigos A, et al. Evaluation of the efficacy and safety of infliximab on psoriatic nails: An unblinded, nonrandomized, openlabel study. Br J Dermatol 2008; 159: 453-6
83. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-66
84. Rigopoulos D, Gregoriou S, Lazaridou E, et al. Treatment of nail psoriasis with adalimumab: An open label unblinded study. J Eur Acad Dermatol Venereol 2010; 24: 530-4
85. Van den Bosch F, Manger B, Goupille P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis 2010; 69: 394-9
86. Galindo MP, Bartlett BL, Gewirtzman A, et al. Etanercept: An overview of its role in the treatment of psoriasis. Expert Opin Drug Metab Toxicol 2008; 4: 305-10
87. Bissonnette R. Etanercept for the treatment of psoriasis. Skin Therapy Lett 2006; 11: 1-4
88. Coelho JD, Diamantino F, Lestre S, et al. Treatment of severe nail psoriasis with etanercept. Indian J Dermatol Venereol Leprol 2011; 77: 72-4
89. Rallis E, Stavropoulou E, Rigopoulos D, et al. Rapid response of nail psoriasis to etanercept. J Rheumatol 2008; 35: 544-5
90. Luger TA, Barker J, Lambert J, et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2009; 23: 896-904
91. Barrera MV, Habicheyn S, Mendiola MV, et al. Etanercept in the treatment and retreatment of psoriasis in daily clinical practice. Eur J Dermatol 2008; 18: 683-7
92. Lawry M. Biological therapy and nail psoriasis. Dermatol Ther 2007; 20: 60-7
93. Krueger GG, Callis KP. Development and use of alefacept to treat psoriasis. J Am Acad Dermatol 2003; 49 (2 Suppl.): S87-97
94. Parrish CA, Sobera JO, Robbins CM, et al. Alefacept in the treatment of psoriatic nail disease: A proof of concept study. J Drugs Dermatol 2006; 5: 339-40
95. Korver JE, Langewouters AM, Van De Kerkhof PC, et al. Therapeutic effects of a 12-week course of alefacept on nail psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 1252-5
96. Cassetty CT, Alexis AF, Shupack JL, et al. Alefacept in the treatment of psoriatic nail disease: A small case series. J Am Acad Dermatol 2005; 52: 1101-2
97. Laws PM, Warren RB. Ustekinumab for the treatment of psoriasis. Expert Rev Clin Immunol 2011; 7: 155-64
98. Krulig E, Gordon KB. Ustekinumab: An evidence-based review of its effectiveness in the treatment of psoriasis. Core Evid 2010; 5: 11-22
99. Patsatsi A, Kyriakou A, Sotiriadis D. Ustekinumab in nail psoriasis: An openlabel, uncontrolled, nonrandomized study. J Dermatolog Treat. Epub 2011 Aug 8